Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00329173
Status:
COMPLETED
Last Update Posted:
2009-03-16
First Post:
2006-05-22
Brief Title:
PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A 6-Week Open-Label Randomised Multicentre Phase IIIb Parallel-Group Study to Compare the Efficacy and Safety of Rosuvastatin 10 mg With Atorvastatin 20 mg in Subjects With Hypercholesterolaemia and Either a History of CHD or Clinical Evidence of CHD
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare reduction of LDL-C and safety between 10mg rosuvastatin and 20mg atorvastatin after 6 weeks treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| D3569C00001 | None | None | None |
| PULSAR | None | None | None |